Preliminary Study on the Effect of Blood Purification Therapy With Dual-cannula in Jugular-femoral Venous
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 主要终点
- vasoactive drugs
研究概览
简要总结
Acute kidney failure (AKI) is one of the most important causes of morbidity and mortality for critical ill patients. The use of blood purification treatment such as renal replacement therapy (CRRT) and plasma exchange has gradually developed into an effective treatment. However, the efficiency of blood purification may be affected by the recirculation of dual-lumen venous catheter for some special patients including patients with vena cava reflux disorder from massive occupations or ascites. For extreme cases like patients with vena cava disconnection or severe obstruction, the traditional blood purification treatment cannot work effectively. Thus, we used the dual-cannula in jugular-femoral venous blood purification therapy in the following two patients and found that it can improve the perfusion of systemic circulation and the prognosis of patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.)
- •presence of superior vena cava and/or inferior vena cava reflux disorders
- •age greater than 18 years
排除标准
- •Inability to establish suitable vascular access
- •Pregnant women
- •Not agreeing to active life support treatment
- •Severe active bleeding
结局指标
主要结局
vasoactive drugs
时间窗: 144 hours after dual-cannula in jugular-femoral venous
doses of vasoactive drugs
ICU mortality
时间窗: 28-day ICU mortality
Measurement of ICU mortality
次要结局
- Cytokine(24hous after dual-cannula in jugular-femoral venous)
